卡塔爾方面表示，無法就美伊協議給出任何時間表。

South Korea's five largest pharmaceutical firms posted combined H1 sales of KRW 4.4996 tln and operating profit of KRW 410.6 bln, up 8% and 18% YoY, respectively, the Financial Supervisory Service disclosure system showed. The group comprises Yuhan Corp., Chong Kun Dang Pharmaceutical, Hanmi Pharmaceutical, GC Green Cross and Daewoong Pharmaceutical. Licensing revenue and overseas operations were key drivers of performance divergence. With the government cutting generic drug prices, market participants expect high-margin innovative drugs and new drug performance will determine H2 earnings.

美國財長貝森特：日本將迎來強勁增長，日本科技行業實力非常強勁。